Benign prostatic hyperplasia (BPH) is an extremely common disease of older men, occurring in more than 70 percent of men over the age of 60. BPH results in substantial morbidity in this patient ...

Gut Microbiota and Benign Prostatic Hyperplasia research highlights new inflammatory pathways and microbiome targets. Learn ...

This clinical overview details the latest evidence-based strategies for diagnosing and treating symptoms of benign prostatic hyperplasia in men.

Driven by a growing patient population, rapid adoption of minimally invasive and robotic technologies, increased use of diagnostic-guided focal therapies, and the ongoing dominance of proven ...

There is a significant positive association between dietary calcium intake and benign prostatic hyperplasia (BPH), according to a study published online May 30 in Translational Andrology and Urology.

The purpose of this manuscript is to provideclinicians, health plan decision makers, and policymakers with highlights of key findings pertainingto our current understanding of the condition ofenlarged ...

Extracts of the berries of saw palmetto, a small palm tree native to the southeastern U.S., are used widely to treat benign prostatic hyperplasia (BPH). In this randomized trial conducted in ...

Entadfi is a fixed-dose combination of finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. The Food and Drug Administration (FDA) has approved Entadfi ...

Many symptoms associated with prostate cancer, like frequent urination or difficulty peeing, may be caused by less-serious concerns. Learn more.

Drug Used for Enlarged Prostate Tied to High Glaucoma Risk The use of alpha-blockers for benign prostatic hyperplasia is tied to an increased risk of developing acute angle-closure glaucoma, a study ...